Pharmaceutics — Instructions for Authors

Please first read the section 'Aims & Scope' to have an overview, and to assess if your manuscript is suitable for this journal.

Shortcuts

iThenticate logo

Please use a template file to prepare your paper.

Submission of Manuscripts

[Return to top]

Manuscript Preparation

  • Paper Format: A4 paper format, the printing area is 17.5 cm x 24.7 cm. The margins should be 1.5 cm on top, 3.5 cm at the bottom and 1.75 cm on both left and right sides of the paper.
  • Formatting / Style: The paper style of Pharmaceutics should be followed. You may download a template file from the Pharmaceutics homepage to prepare your paper. The full titles and the cited papers must be given. The style of Journal of Chemical Information and Computer Sciences is acceptable. Reference numbers should be placed in square brackets [ ], and placed before the punctuation; for example [4] or [1-3], and all the references should be listed separately and as the last section at the end of the manuscript.
  • Reference Formatting: See the Reference Preparation Guide. References should be numbered according to the order in which they appear in the text.
  • Reference Preparation: References should preferably be prepared with EndNote®, ReferenceManager™ or a similar bibliography software package. If references are prepared manually they must be checked for integrity and correctness (you may use ISI Web of Knowledge, PubMed/MEDLINE or Google Scholar). The Editorial Office will charge additional CHF 10 per citation for which extensive corrections must be made.
  • Authors List and Affiliation Format: Authors' full first and last names must be given. Abbreviated middle name can be added. For papers written by various contributors a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties, who provided only minor contributions, should be listed under Acknowledgments only. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
  • Abstract and Keywords: The abstract should be prepared as one paragraph (about 200 words). A list of three to ten keywords must be given, and placed after the Abstract.
  • Figures, Schemes and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and a explanatory title must be added. Tables should be inserted into the main text, and numbers and titles for all tables supplied. All table columns should have an explanatory heading. Please supply legends for all figures, schemes and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table and after a figure or a scheme.
  • Abstract/Table of Contents Graphic: Authors are encouraged to provide a graphical representation of the paper (in either JPEG, GIF, PNG or PDF format) to be used as a graphic of the paper, along with the abstract, on the Table of Contents. The graphic should not exceed 500 pixels width/height. As an example, authors may review the abstract graphic of following papers:
    - http://www.mdpi.com/1424-8220/9/1/490
    - http://www.mdpi.com/1420-3049/14/1/378
  • Electronic Supplementary Information (ESI): Conference slides, video sequences, software, etc., can be included with the submission and published as supplementary material. Please read the information about Supplementary Material Deposit beneath.

[Return to top]

Clinical Trials

Original research articles reporting results of clinical trials must contain a separate "Conflict of Interest" statement to be placed before the "Acknowledgments" and "References" sections at the end of the manuscript. Financial support for the study must be fully disclosed under "Acknowledgments" section. Finally, authors are strongly encouraged to register their clinical trials with an international clinical trials register, and to cite the registration number of the trial.

Potential Conflicts of Interest

It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here "The authors declare no conflict of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Financial support for the study must be fully disclosed under "Acknowledgments" section.It is the authors' responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state here "The authors declare no conflict of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Financial support for the study must be fully disclosed under "Acknowledgments" section.

Review / Referees

Authors should suggest at least five potential referees with the appropriate expertise, although the Editor will not necessarily approach them. Please provide as detailed contact information as possible (address, homepage, phone, e-mail address). The proposed referees should be experts in the field who can provide an objective report - they should not be current collaborators of the authors nor have published with any of the authors of the manuscript within the last 5 years. Proposed referees should be from different institutions than the authors. You may identify appropriate Editorial Board members of the journal as potential referees. Another possibility is to select referees from among the authors that you frequently cite in your paper.

[Return to top]

English corrections

This journal is published in English, so it is essential that for proper refereeing and quick publication all manuscripts are submitted in grammatically correct English. For this purpose we ask that non-native English speakers ensure their manuscripts are checked before submitting them for consideration. We suggest that for this purpose your manuscript be revised by an English speaking colleague before submission. Authors can also use the services of American Journal Experts (AJE) for this purpose. Authors of articles submitted to MDPI journals benefit of a one-time 10% discount on AJE's charges. Simply follow the above link to make use of the referral discount. Additional fees of CHF 250 will be paid by authors if extensive English corrections must be done by the editors.

[Return to top]

MDPI Publication Ethics Statement

Pharmaceutics is a member of the Committee on Publication Ethics (COPE). MDPI takes the responsibility to enforce a rigorous peer-review together with strict ethical policies and standards to ensure to add high quality scientific works to the field of scholarly publication. Unfortunately, cases of plagiarism, data falsification, inappropriate authorship credit, and the like, do arise. MDPI takes such publishing ethics issues very seriously and our editors are trained to proceed in such cases with a zero tolerance policy.

CrossCheck/iThenticate

Pharmaceutics is a member of CrossCheck powered by iThenticate. iThenticate is a plagiarism screening service that verifies the originality of content submitted before publication. iThenticate checks submissions against millions of published research papers, and billions of web content. Authors are encouraged to use iThenticate to screen their work before submission by visiting www.ithenticate.com.

Supplementary Material Deposit

  • We wish to encourage the submission of supplementary data in electronic formats, so that important chemical, structural or scientific information is retained in full. Spectral data (NMR, IR, Raman, ESR, etc) can be submitted in JCAMP (.jdx) format.
  • 3D coordinate structures (in pdb, mol, xyz or other common formats), if available, should also be submitted.
[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert